H.C. Wainwright reiterates a Buy rating on Lava Therapeutics with a $9 price target after the company presented initial clinical data from its ongoing Phase 1/2a study evaluating LAVA-1207 for the treatment of refractory metastatic castration-resistant prostate cancer. The analyst is encouraged by LAVA-1207’s initial results, saying the drug not only demonstrated a favorable safety profile but also showed early signal of anti-tumor activity. The data bode well for LAVA-1207’s therapeutic potential in mCRPC and warrant further study of the drug, the analyst tells investors in a research note. The firm views the selloff in the shares on the data as unwarranted.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LVTX:
- Lava Therapeutics announces initial data from Phase 1/2a study of LAVA-1207
- LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium
- LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer
- Lava Therapeutics appoints Charles Morris as CMO
- LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
